Video of the Week | National Apprenticeship Week 2019 | Advanced Therapies

During National Apprenticeship Week apprentices and participating employers gathered at Oxford BioMedica to discuss how the first of its kind advanced therapies apprenticeship programme is key to meeting the industry demands for advanced therapies. Dr Ian Campbell, interim Executive Chair, Innovate UK, delivered the keynote speech and highlighted the Government’s commitment to the programme. Other highlights of the day included a Q&A session with current apprentices and the launch of three new programmes in regulatory affairs, senior management and the Scottish modern apprenticeship in life sciences.

Congenica Co-founder and Scientific Director Dr Matthew Hurles Elected to Fellowship of the Royal Society

Cambridge, United Kingdom – 18 April, 2019 - Congenica, the global diagnostic decision support platform provider, congratulates its co-founder and Scientific Director, Dr Matthew Hurles, FMedSci FRS, who has been elected to Fellowship of the Royal Society, the UK’s most prestigious scientific organisation.

BioDivide Ltd Announces the Launch of the Next Generation Equine Stem Cell Therapy

BioDivide has developed a new stem cell technology for horses called StemPlan. The launch of StemPlan will be supported by a series of CPD events to provide veterinarians with the most up-to-date information about equine regenerative medicine.

Coulter Partners places Chairman and Chief Executive Officer for OxStem

Coulter Partners was very pleased to partner with OxStem Limited, a leading biotechnology company focussed on regenerative medicine, to secure the appointment of Dr Stuart Collinson as Chairman and Chief Executive Officer.

Blue Earth Diagnostics Announces Addition of Axumin® (fluciclovine (18F)) to EAU Guidelines for imaging in patients with biochemical recurrence in Prostate Cancer

Oxford, UK – April 16, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that Axumin (fluciclovine (18F)) has recently been added to the European Association of Urology (EAU) 2019 Clinical Practice Guidelines in Oncology for Prostate Cancer (PCa). The EAU PCa Guidelines assist clinicians in making informed decisions, taking into consideration the scientific data available and individual circumstances of patients.

LifeArc® licenses lead stage molecules to Daiichi Sankyo

LifeArc, one of the UK’s leading medical research charities, has signed a deal to license an ion channel drug discovery programme to Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo). Small molecules, optimised as part of the programme, are capable of affecting the sensitivity of neurons, show efficacy in treating pain and will undergo further pre-clinical development.

CEO Update | Monday 15 April 2019

Easter is fast approaching, Parliament has risen for a two week recess and MPs have left Westminster to contemplate their next steps after yet another dramatic Brexit week.

Enesi Pharma and BARDA Drive enter Public-Private Partnership to Develop ImplaVax® Solid Dose Vaccine Delivery Technology against Influenza

The programme aims to provide a cost-effective technological innovation that improves vaccination uptake, coverage, compliance and preparedness.

Astex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval

Further Milestone from Janssen on NDA Approval by the US FDA of BALVERSA™ (erdafitinib) for the Treatment of Urothelial Cancer

Recruitment Open for LifeArc and AUTM Foundation Technology Transfer Fellowship

Today LifeArc, the medical research charity, and the Association of University Technology Managers (AUTM) Foundation announced that recruitment is open for their Technology Transfer Fellowship 2019-2020. The LifeArc-AUTM Fellows Programme is a one-year training fellowship that trains promising life scientists to become the next generation of highly skilled technology transfer specialists. The deadline for applications is 7 July 2019.